Forest Laboratories to present linaclotide data at DDW 2012

Forest Laboratories will be presenting new clinical data on its investigational irritable bowel syndrome (IBS) therapy linaclotide during Digestive Disease Week (DDW) 2012.

The company and its development partner Ironwood Pharmaceuticals will attend the industry conference in San Diego from May 19th to 22nd this year in order to showcase linaclotide-related data in one oral presentation and 16 poster presentations.

Linaclotide is an investigational guanylate cyclase type-C agonist designated for the treatment of IBS with constipation and has shown promise in previous clinical studies.

At DDW 2012, trial data will be presented that underlines the benefits the drug can provide in addressing the most severe abdominal symptoms of the disease.

Further phase III results will also demonstrate its safety and efficacy benefits compared to placebo among a variety of patient groups.

In Europe, linaclotide is being developed and commercialised in partnership with Almirall and was submitted for regulatory approval last year, with Almirall planning to sell it under the name Constella.